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Summary: Agarose-bound asialofetuin functions äs an insoluble sialyl group acceptor in a simplified assay
for sialyl transferase (CMP-neuraminate: £>-galactosyl-glycoprotein N-acetylneuraminyl transferase; EC
2.4.99.1) in serum. Since sialyl transferase levels in serum are elevated in a large number of malignant
conditions, the simplified assay is of use for clinical monitoring in tumour therapeutic programmes.*
Bereitung und Anwendung eines trägergebundenen Akzeptors für die Bestimmung der Sialyltransferasc-Aklivität
im Serum
Zusammenfassung: Kovalent an Agarose gebundenes Asialofetuin dient als unlöslicher N-Acetylneuramin-
säure-Akzeptor in einer vereinfachten Methode für die Bestimmung der Sialyltransferase im Serum (CMP-
Neuraminat: /)-galactosyl-glycoprotein N-acetylneuraminyltransferase, EC 2.4.99.1). Nachdem die Sialyl-
transferase-Aktivität im Serum bei einer Vielzahl maligner Erkrankungen erhöht ist, eignet sich die hier
beschriebene Methode insbesondere für die Enzymbestimmung im Rahmen von Verlaufskontrollen.
Introduction
Recently, a number of reports have appeared de-
scribing augmented levels of sialyl transferase (EC
2.4.99.1) (l, 2) in sera from cancer patients. In this
context, others and ourselves (3 — 5) have demon-
strated significant correlations between augmented
serum sialyl transferase activity and tumour mass,
stage of disease, and extent of metastatic invol-
vement. In the course of these studies, we have found
that the resülts obtained by the classical serum sialyl
transferase assay, based on incorppration of radio-
active N-acetylneuraminic acid (NeuAc) into gly-
coprotein,, followed by precipitation of glycoprotein
with acid (16), are subject to unduly large variations,
and are thus of limited value. Siinilar problems have
been noted by others (7). For this reason, we have
developed a simplified assay procedure for serum
sialyl transferase based on the use of asialofetuin äs
a earrier-bound, insoluble sialyl group acceptor. This
test affords resülts sufficiently reliable to be employed




Scpharose 4B (Pharmacia Fine Chemicals A. B., Uppsala,
Sweden); fetuin (GIBCO Diagnostics, Madison, WI, 53713);
cyanogen bromide (Serva Feinchemikalien, Heidelberg, West-
Germany); Cytidine-5'-monophospho[14C]N-acetylneuraminic
acid (CMP-NeuAc), spec. act., 5.5—11.0 GBq/mmol; sodium
boro-[3H]hydride, spec. act., 185-740 GBq/mmol; (The Ra-
diochemicaJ Centre, Amersham U. K.); galactose oxidase (ICN
Biochemicals Inc., Cleveland OH, USA), and Insta-gel (Pack-
afd Instrument Comp., Downers Grove, IL, USA). All other
chemicals used were of the purest grade available.
Sialyl transferase
In all experiments, the source of the enzyme was human serum
obtained from whole blood. Blood was taken either from cancer
patients with proven tumours or from healthy volunteers. Sam-
ples from individuals, or pooled material, were routinely stored
at — 20 °C for up to l month or, for specific experiments, under
different conditions äs indicated in the text.
Preparative procedures
Asialofetuin was prepared by mild acid hydrolysis of fetuin,
following the procedure of Spiro et al. (8). Tritium-labelled
asialofetuin ([3H]asialofetuin) was prepared from asialofetuin
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by oxidation of tcrminal galactosyl rcsidues, catalysed by
galactose oxidasc, followed by reduction with sodium boro-
[3H]hydride, using essentially the method described by Morett
et al. (9). Cyanogen-bromide activation of Sepharose 4B, and
coupling of asialofetuin, were performed s described by CM-
atrccasas et al. (10), using 12.5g of solid cyanogen bromide
(CNBr) for 100g wet weight of Sepharose 4B. For covalent
coupling, 4 mg asialofetuin were used per l g of cyanogen
bromide-activated Sepharose 4B. After rempving the reagents
of the coupling reaction, the insoluble sialyl acceptor-complex
(asialofetuin-Sepharose 4B) was suspended in the incubation
buffer of the enzymatic reaction (0.01 mol/1 Tris-HCl pH 7.3
containing 0.005 mol/1 MnCl2). The final concentration was
7 ml of sedimented acceptor-complex in a total buffer volume
of 10 ml. This Suspension was stored at 4 °C.
Protein d e t e r m i n a t i o n s
Protein determinations were performed according to Lowry et
al. (11). Protein bound to Sepharose 4B was estimated accord-
ing to Koelsch et al. (12).
Assay procedures for serum sialyl transferase using
a soluble acceptor
A slightly modified procedure of Bosman et al. was used (6).
Tris-HCl-buffer, (0.01 mol/1; pH 7.3) (100 μΐ), containing 0.005
mol/1 manganese Chloride, and asialofetuin (15 μg protein),
were mixed with serum samples (100 μΐ) and CMP-[14C]NeuAc
solution (ca. 0.5 nmol in 5 μΐ, spec. act. 5.5 — 11.0 GBq/mmol).
The mixtures were incubated at 37 °C for 30 min. Following
incubation, the soluble radioactivity was removed either by
precipitating the glycoprotein with phosphotungstic acid, or by
passage of the reaction mixture over small ion-exchange co-
lumns (Dowex 1X8 OH-form, 5-15 mm) (13).
Asialo-fetuin • Sialo-fetuin















Fig. 1. Schcmatic diagram for the procedure of the serum sialyl ·
transferase delermination.
Results
Properties of the insoluble asialofetuin-Se-
pharose 4B-acceptor complex
Optimal ratio of asialofetuin to Sepharose 4B
Maximal acceptor activity was robserved when 25.4
rng of asialofetuin protein per l g (dry weight) of
CNBr-activated Sepharose 4B was used in the cou-
pling reaction, resulting in 7.8 μg protein covalently
bound per l mg of acceptor-complex (dry weight).
When the amount of asialofetuin bound to l mg (dry
weight) of CNBr-activated Sepharose 4B exceeded 50
μg (protein), the subsequent enzymatic transfer of
sialyl groups to the acceptor was significantly im-
peded.
Stability of the insoluble acceptor
Samples of [3H]asialofetuin-Sepharose 4B-complex
and of non-radioactive asialofetuin-Sepharose 4B
were suspended in the incubation buffer and stored
at 4 °C or at room temperature. l, 2, 3, and 6 months
after preparation, the amounts of bound protein were
detennined by counting radioactivity, and by color-
imetric assay of asialofetuin (12). The acceptor-com-
plex, when stored at 4 °C, is stable for 2 months.
During the third month after preparation a fraction
of 0.8, and, after 6 months of 0.65 remains. After
two months at rpom temperature, the acceptor-com-
plex had lost a fraction of 0.2, and within 6 months
a fraction of 0.35, of the protein originally bound.
Assay procedure for serum sialyl transferase
using the insoluble sialyl group acceptor
The procedure for the serum sialyl transferase de-
termination is schematically depicted in figure 1.
Asialofetuin-Sepharose 4B Suspension (100 μΐ, cor-
responding to 1.8 mg dry weight, with an asialofetuin
content of 14 μg protein), CMP-[14C]Ne Ae (5 μΐ,
spec. act. 5.5-11.0 GBq/mmol) and the serum sam-
ples (100 μΐ) were mixed in plastic tubes and in^
cubated in a 37 °C water bath for 30 min with gentle
shaking. S bsequendy, the soluble radioactivity was
removed by washing the acceptor complex with four
times l ml each of 3 mol/1 guanidinum Chloride so-
lution. This washing solution is preferable to water
or l mol/1 sodium Chloride, s washing with the latter
resulted in a higher proportion of unspeqifically
bound radioactivity in the beads. Care was taken
during removal of the supernatants after each Sedi-
mentation. Following the final wash, the sedimented
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beads were dissolved by adding 2 mol/1 sulphuric acid
(l ml) and allowing to stand at 80 °C for 20 min.
After cooling, the clear, colourless Solutions were
quantitatively transferred into counting vials con-
taining Insta-gel® (10 ml). A somewhat lower count-
ing efficiency was observed when the acceptor com-
plex, following the final wash, was quantitatively
transferred into a scintillation vial, dispersed in a
mixture of water and Insta-gel®, and counted. Radio-
activity was determined using a Tri-Carb liquid scin-
tillation counter, and was converted1) into μηιοΐ/min
of serum sialyl transferase per Ihre of serum.
Incubation conditions
The dependence of the binding of NeuAc to carrier-
bound asialofetuin on the duration and temperature
of the incubation is shown in figure 2. When the
reaction mixtures are incubated at 37 °C, a linear
increase of radioactivity becoining bound is observed
for up to 150 min, and at room temperature, for up
to 180 min. Thereafter, slightly less NeuAc is found
incorporated into the glycoprotein acceptor. Serum
sialyl trasferase is apparently denatured by heating










Fig. 2. Dependence of the amounts of N-acetylneufaminic acid
incorporated into carrier-bound asialofetuin on the
duration and temperature of incubation.
To determine the pH Optimum of the serum sialyl
transferase reaction, the acceptor epmplex was s -
spended in various buffefs coVering the pH r nge
from 6.5 to 8.0. A 0.01 mol/1 Tris-HCl buffer (pH 7.3)
was found optimal. In 0.01 mol/1 Tris-maleate, or
sodium cacodylate buffers, less NeuAc became in-
corporated at all pH values tested. Furthermore, the
presence of m nganese Chloride is necessary for op-
') One unit of serum sialyltransferase is defmed s the amount
of enzyme which catalyses the transfer of l μιηοΐ/ππη of
[I4C]NeuAc into asialofetuin-Sepharose 4B-complex under
the conditions described above.
timal enzyme activity. When magnesium Chloride was
used instead of manganese chloride, a reduction in
enzyme activity by a factor of ca. 0.85 was observed.
In the absence of divalent metal ions, the rate of
incorporation was lower by a factor of about 0.75.
Serum sialyl transferase activity decreases by a frac-
tion of ca. 0.2 when serum samples are kept at room
temperature for 24 h. Thus, after blood collection,
clotting and centrifugation, samples should promptly
be cooled to -20°C. At this temperature, the sera
can be stored for 3 months without significant loss
of enzyme activity. On storage for 6 months, a de-
crease of up to one half is observed. The addition of
blood clotting Inhibitors to whole blood results in
decreased enzyme activity ofplasma samples (ca. one
half using heparin and 0.4 using sodium citrate).
Variations of the glycoprotein content in individual
serum samples, frequently associated with vario s
pathological conditions, have practically no mfluence
on the measured serum sialyl transferase activities
when the insoluble acceptor-complex assay System is
used. Practically all of the endogenous acceptors to
which radioactive sialic acid may be transferred in the
enzymatic reaction are removed during the washing
procedure, s is the non-incorporated radioactivity.
Thus, it is not necessary to run parallel blanks, since
the amount of radioactivity unspecifically bound to
the beads is very low and constant.
Accuracy and r e p r o d u c i b i l i t y of
sialyl t ransferase d e t e r m i n a t i o n s
serum
Pipetting of the acceptor from suspensions containing
varying ratios of sedimented resin to buffer results in
a Variation coefficient of 5.1 ± 1.5% with respect
to the amount of acceptor complex. Therefore, the
suspensions were gently stirred during pipetting.
When a serological pipette was used to deliver the
Suspension of the insoluble acceptor (6 consecutive
experiments with 3 parallel determinations each), a
Variation coefficient of 4.3% for the dry weight and
2.2% for the radioactivity of [3H]asialofetuin-
Sepharose was calculated. However, when a constant
delivery, disposable tip micropipette was used, the
Variation coefficient was found to be ca. 30%, both
with respect to dry weight and radioactivity.
To locate further potential errors due to incorrect
handling of this assay System, the amount of the
acceptor complex and sialic acid donor (CMP-
[I4C]NeuAc), and the incubation time were varied
according to the "central composible rotable design"
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(14). With the data obtained from 6 cancer patients
and 6 controls, two different equations were
formulated.
y„ = 50.5 + 5.8
x- 100 (eq. 1)
(residual mean square = 19.9)
-100 (eq.2)
(residual mean square = 26.8)
yn = units serum sialyl transferase, normal healthy
subjects
yc = units serum sialyl transferase, cancer patients
= % Variation in the amount of acceptor com-
plex
z = % Variation in the time of incubation (min)
A Variation of ± 20% in the amount of Substrate
(CMP-[14C]NeuAc) has no influence on the serum
sialyl transferase activity measured. Decreasing or
increasing the amount of acceptor complex causes a
proportional change of the serum sialyl transferase
activity. Interestingly, extension of the incubation
period results in an increased incorporation of radio-
activity, which is 1.10 times greater for sera from
cancer patients than for control sera.
To demonstrate the reliability of the serum sialyl
transferase determinations in a practical Situation,
serum sialyl transferase was determined daily in 6
healthy controls (4 parallels) over a period of five
consecutive days. Within this time, the individual
enzyme levels were found to vary in the ränge of 2.31
± 0.99%. Corresponding figures were obtained by
analysing sera from cancer patients (15). In a follow-
up period of 176.0 ± 87.1 days of 31 relapse-free
patients after surgical removal of large bowel cancer,
individual variations of 13.9 ± 9.4% in serum sialyl
transferase levels were found.
Discussion
The use of an insoluble glycoprotein acceptor-com-
plex in serum sialyl transferase determinations äs
described here is more precise and more convenient
than the classical assay using a soluble glycoprotein
acceptor.
The "classical" method of serum sialyl transferase
determinations, based on acid precipitation of gly-
coprotein, and removal of non-incorporated radio-
activity by repeated washing, centrifugatiori and re-
suspension, has a low precision with a Variation
coefficient of 14—24%. Anqt^er procedure (6),
whereby non-incorporated radioactivity is removed
by washing the acid precipitates on filter plates, re-
sults in slightly better precision (coefficient of Vari-
ation 13 — 17%). In genefal, acid denaturation of the
serum proteins together with the NeuAc-accepting
glycoprotein results in inhomogeneous and gummy
precipitates. These materials adhere to the surfaces
of the reaction tubes and of the filter discs, apparently
embedding non-incorporated radioactivity. Even with
lengthy washing procedures, the removal of soluble
radioactivity tended to be erratic on our hands.
The use of an insoluble glycoprotein acceptor com-
plex circumvents these difficulties. The resin used can
easily and reproducibly be freed from non-in-
corporated radioactivity (coefficient of Variation
3 — 7%). The published method using small ion
exchange columns (13) is similarly convenient in this
respect. However, a separate column is required for
each determination, and the disposal of the used,
radioactively contaminated columns is inconvenient.
Recently another simplified procedure for the de-
tection of serum sialyl transferase has been reported
(16). Serum samples incubated with labeled nücleo-
tide sugar and glycosylated endogenous acceptor
molecules were absorbed to Con A Sepharose and
quantitated by scintillation counting.
A distinct advantage of using an insoluble acceptor
compared to the ion exchanger method is the fact
that endogenous serum acceptors do not influence
the assay System, being removed from the acceptor-
complex by washing. Thus, the measured radio-
activity can be directly evaluated to mol/1 by sub-
traction of the blank (the amount of radioactivity
which is unspecifically bound to the carrier) äs a
constant value. The possibility of dispensing with the
correction for endogeneous sialyl group acceptors
affords 50% savings in capacity needed for the serum
sialyl transferase determinations.
It is hoped that the reproducibility and reliability of
this serum sialyl transferase determination, äs per-
formed by the assay method described will contribute
to further clinical studies regarding the significance
of the tumour-associated increase in sialyl transferase
levels in serum.
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